News
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
The U.S. Food and Drug Administration approved Sarepta's Elevidys, the first gene therapy for DMD, last year and allowed the expanded use of the drug in June.
Summary Sarepta Therapeutics' stock plummets after its gene therapy drug ELEVIDYS fails to meet its primary endpoint in a confirmatory study. SRPT had previously secured accelerated approval for ...
CAMBRIDGE, Mass., April 04, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS ...
Sarepta shares fell ~40% in premarket after reporting a second patient death linked to Elevidys. Sarepta halted Elevidys shipments for non-ambulatory patients and paused dosing in the ENVISION ...
The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...
Sarepta shares dropped 27% after the first death in March. BMO lowered its price target to $70, warning of risks to 2025 revenue guidance and potential regulatory action affecting non-ambulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback